Association of Single Nucleotide Polymorphisms in Glycosylation Genes with Risk of Epithelial Ovarian Cancer

Studies suggest that underglycosylation of the cell membrane mucin MUC1 may be associated with epithelial ovarian cancer. We identified 26 genes involved in glycosylation and examined 93 single nucleotide polymorphisms (SNP) with a minor allele frequency of ≥0.05 in relation to incident ovarian cancer. Cases were ascertained at the Mayo Clinic, Rochester, MN (n = 396) or a 48-county region in North Carolina (Duke University; n = 534). Ovarian cancer–free controls (n = 1,037) were frequency matched to the cases on age, race, and residence. Subjects were interviewed to obtain data on risk factors and a sample of blood for DNA and genotyped using the Illumina GoldenGate assay. We excluded subjects and individual SNPs with genotype call rates of <90%. Data were analyzed using logistic regression, with adjustment for age and residence. We fitted dominant, log additive, and recessive genetic models. Among Caucasians, nine SNPs in eight genes were associated with risk at P < 0.05 under at least one genetic model before adjusting for multiple testing. A SNP in GALNT1 (rs17647532) was the only one that remained statistically significant after Bonferroni adjustment for multiple testing but was not statistically significant in Hardy-Weinberg equilibrium among controls. Haplotype analyses revealed a global association of GALNT1 with risk (P = 0.038, under a recessive genetic model), which largely reflected a decreased risk of one haplotype (0.10 frequency; odds ratio, 0.07; P = 0.01) compared with the most common haplotype (0.39 frequency). These results suggest that genetic polymorphisms in the glycoslyation process may be novel risk factors for ovarian cancer. (Cancer Epidemiol Biomarkers Prev 2008;17(2):397–404)

[1]  B. Rosen,et al.  Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. , 2001, American journal of human genetics.

[2]  H. Lynch,et al.  Hereditary ovarian cancer. Pedigree studies, Part II. , 1991, Cancer genetics and cytogenetics.

[3]  Sandra J. Gendler.  MUC1, The Renaissance Molecule , 2001, Journal of Mammary Gland Biology and Neoplasia.

[4]  Lawrence A Tabak,et al.  All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases. , 2003, Glycobiology.

[5]  R. Dodge,et al.  Mucin gene expression in ovarian cancers. , 1998, Cancer research.

[6]  Lynette M. Smith,et al.  Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125) , 2006, Modern Pathology.

[7]  J. Prat,et al.  Hereditary ovarian cancer. , 2005, Human pathology.

[8]  R. Dahiya,et al.  Heterogeneity of mucin gene expression in normal and neoplastic tissues. , 1993, Cancer research.

[9]  C. Wahlberg.  Tubal ligation, hysterectomy, and risk of ovarian cancer. , 1994, JAMA.

[10]  D. Cramer,et al.  Incessant Ovulation, Mucin 1 Immunity, and Risk for Ovarian Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[11]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[12]  D. Schaid,et al.  Score tests for association between traits and haplotypes when linkage phase is ambiguous. , 2002, American journal of human genetics.

[13]  B. Henderson,et al.  Reproductive, genetic, and dietary risk factors for ovarian cancer. , 1988, American journal of epidemiology.

[14]  S. Tsuji,et al.  Localization of a novel susceptibility gene for familial ovarian cancer to chromosome 3p22-p25. , 2001, Human molecular genetics.

[15]  D. Thomas,et al.  Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[16]  A. Whittemore,et al.  Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee. , 1988, American journal of epidemiology.

[17]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[18]  V. Cullins,et al.  Female sterilization. Evidence. , 2000, Obstetrics and gynecology clinics of North America.

[19]  J. Hollister,et al.  Engineering lepidopteran insect cells for sialoglycoprotein production by genetic transformation with mammalian β1,4-galactosyltransferase and α2,6-sialyltransferase genes , 2001 .

[20]  A. Russo,et al.  Hereditary ovarian cancer. , 2009, Critical reviews in oncology/hematology.

[21]  R. Berkowitz,et al.  Conditions Associated with Antibodies Against the Tumor-Associated Antigen MUC1 and Their Relationship to Risk for Ovarian Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[22]  J. van den Born,et al.  Antibody-based assay for N-deacetylase activity of heparan sulfate/heparin N-deacetylase/N-sulfotransferase (NDST): novel characteristics of NDST-1 and -2. , 2003, Glycobiology.

[23]  R. Vierkant,et al.  Estrogen Bioactivation, Genetic Polymorphisms, and Ovarian Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[24]  S. Baldus,et al.  MUC1 and the MUCs: A Family of Human Mucins with Impact in Cancer Biology , 2004, Critical reviews in clinical laboratory sciences.

[25]  C. Boland,et al.  Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. , 1995, Journal of the National Cancer Institute.

[26]  A. Whittemore,et al.  Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use. , 1988, American journal of epidemiology.

[27]  A. Thathiah,et al.  MUC1: A multifunctional cell surface component of reproductive tissue epithelia , 2004, Reproductive biology and endocrinology : RB&E.

[28]  H. Lynch,et al.  Hereditary gynecologic cancer. , 1998, Cancer treatment and research.

[29]  Chia-Hung Liu,et al.  FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization , 2006, Nucleic Acids Res..

[30]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[31]  M. Hollingsworth,et al.  Substrate Specificities of Three Members of the Human UDP-N-Acetyl-α-d-galactosamine:Polypeptide N-Acetylgalactosaminyltransferase Family, GalNAc-T1, -T2, and -T3* , 1997, The Journal of Biological Chemistry.

[32]  S. Lehrer.  Tubal ligation, hysterectomy, and risk of ovarian cancer. , 1994, JAMA.

[33]  Julian Peto,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.

[34]  W. Willett,et al.  Tubal Ligation, Hysterectomy, and Risk of Ovarian Cancer: A Prospective Study , 1993 .

[35]  J. Boyd,et al.  Hereditary ovarian cancer: molecular genetics and clinical implications. , 1997, Gynecologic oncology.

[36]  J. Gordon,et al.  Glycans as legislators of host-microbial interactions: spanning the spectrum from symbiosis to pathogenicity. , 2001, Glycobiology.

[37]  Leif E. Peterson,et al.  Characterization of BRCA1 and BRCA2 mutations in a large United States sample. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[39]  M. Morgan,et al.  Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. , 2000, Epidemiology.